Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Pyxis Oncology (PYXS) will present MICVO Phase 1 monotherapy data in a late-breaking oral session on November 19, 2026.

Rhea-AI Summary

Pyxis Oncology (PYXS) will present MICVO Phase 1 monotherapy data in a late-breaking oral session on November 19, 2026. The study involves previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma.

The presentation is scheduled for the EORTC-NCI-AACR Symposium in Barcelona, running November 18–20, 2026. Two posters on November 18 will cover MICVO’s mechanism of action in laboratory studies and its combination with EGFR-targeted therapy in patient-derived tumor models. The announcement provides presentation details rather than clinical results.

Key Terms

monotherapy, hnscc, antibody-drug conjugate, extracellular matrix

4 terms

monotherapy medical

"micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

hnscc medical

"head and neck squamous cell carcinoma (HNSCC)"

HNSCC stands for head and neck squamous cell carcinoma, a type of cancer that starts in the flat lining cells that cover the surfaces of the mouth, throat and related structures. It matters to investors because treatments, clinical trial results, regulatory approvals or changes in diagnosis rates can directly affect the commercial prospects and valuation of companies developing therapies or diagnostics for this disease—think of it as a market signal tied to demand for specific medical products.

antibody-drug conjugate medical

"MICVO is an antibody-drug conjugate (ADC)"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

extracellular matrix technical

"a non-cellular structural component of the tumor extracellular matrix"

A network of proteins and other molecules that sits outside cells and gives tissues their shape, strength and a medium for cells to send signals and move — like the scaffolding and wiring inside a building. Investors care because changes to this matrix play a major role in diseases, wound healing and tissue repair, making it a common target for drugs, medical devices and diagnostics that can drive regulatory decisions and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral presentation on micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) at the 38^th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, November 18 - November 20, 2026.

In addition, Pyxis Oncology will present two posters highlighting preclinical research involving MICVO during the symposium’s antibody-drug conjugates session.

Oral Presentation Details:

Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Faye M. Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Proffered Papers: Clinical Trials
Abstract number: 3LBA
Date and time: Thursday, November 19, 2026, from 10:00 a.m. - 11:30 a.m. CET
Location: Room 111 + 112

Poster Presentation Details:

Poster Title: In vitro characterization of the mechanism of action of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin
Session Title: Antibody-drug conjugates
Session Day: Wednesday, November 18, 2026, from 12:00 p.m. - 7:00 p.m. CET
Location: Exhibition Hall
Poster Board Number: PB-054

Poster Title: Micvotabart pelidotin in combination with EGFR-targeted therapy improves duration of response in HNSCC PDX models
Session Title: Antibody-drug conjugates
Session Day: Wednesday, November 18, 2026, from 12:00 p.m. - 7:00 p.m. CET
Location: Exhibition Hall
Poster Board Number: PB-079

About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Pyxis Oncology Contact
IR@pyxisoncology.com